Free Trial

MannKind (MNKD) Competitors

MannKind logo
$3.58 -0.16 (-4.28%)
Closing price 07/1/2025 04:00 PM Eastern
Extended Trading
$3.60 +0.02 (+0.59%)
As of 09:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MNKD vs. LGND, BCRX, FOLD, CLDX, INVA, DVAX, OPK, NVAX, GERN, and RGLS

Should you be buying MannKind stock or one of its competitors? The main competitors of MannKind include Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Innoviva (INVA), Dynavax Technologies (DVAX), OPKO Health (OPK), Novavax (NVAX), Geron (GERN), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry.

MannKind vs. Its Competitors

Ligand Pharmaceuticals (NASDAQ:LGND) and MannKind (NASDAQ:MNKD) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

Ligand Pharmaceuticals presently has a consensus target price of $146.14, indicating a potential upside of 29.84%. MannKind has a consensus target price of $10.33, indicating a potential upside of 188.64%. Given MannKind's stronger consensus rating and higher possible upside, analysts clearly believe MannKind is more favorable than Ligand Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ligand Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
MannKind
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.29

Ligand Pharmaceuticals has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, MannKind has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.

MannKind has a net margin of 10.12% compared to Ligand Pharmaceuticals' net margin of -73.07%. Ligand Pharmaceuticals' return on equity of -7.83% beat MannKind's return on equity.

Company Net Margins Return on Equity Return on Assets
Ligand Pharmaceuticals-73.07% -7.83% -6.92%
MannKind 10.12%-32.41%10.85%

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 7.0% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 3.0% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Ligand Pharmaceuticals and Ligand Pharmaceuticals both had 6 articles in the media. Ligand Pharmaceuticals' average media sentiment score of 0.90 beat MannKind's score of 0.62 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ligand Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MannKind
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive

MannKind has higher revenue and earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ligand Pharmaceuticals$167.13M12.99-$4.03M-$7.12-15.81
MannKind$285.50M3.81$27.59M$0.1035.80

Summary

MannKind beats Ligand Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get MannKind News Delivered to You Automatically

Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MNKD vs. The Competition

MetricMannKindMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.14B$2.85B$5.48B$8.94B
Dividend YieldN/A2.69%5.38%4.12%
P/E Ratio35.8021.1726.2219.74
Price / Sales3.81262.85394.92109.12
Price / Cash26.9541.8936.4957.06
Price / Book-12.347.237.915.37
Net Income$27.59M-$55.05M$3.15B$248.34M
7 Day Performance-7.01%-0.60%0.75%1.67%
1 Month Performance-16.55%3.77%3.46%4.56%
1 Year Performance-28.83%2.20%34.60%18.42%

MannKind Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MNKD
MannKind
3.0655 of 5 stars
$3.58
-4.3%
$10.33
+188.6%
-29.7%$1.14B$285.50M35.80400High Trading Volume
LGND
Ligand Pharmaceuticals
4.7324 of 5 stars
$113.68
-0.4%
$146.14
+28.6%
+32.7%$2.19B$167.13M-15.9780
BCRX
BioCryst Pharmaceuticals
4.4671 of 5 stars
$8.96
-4.3%
$16.89
+88.5%
+34.9%$1.87B$450.71M-34.46530Trending News
Analyst Forecast
Analyst Revision
FOLD
Amicus Therapeutics
4.0388 of 5 stars
$5.73
-3.4%
$16.22
+183.1%
-40.4%$1.76B$528.29M-63.66480
CLDX
Celldex Therapeutics
2.7723 of 5 stars
$20.35
+0.3%
$50.11
+146.2%
-45.6%$1.35B$7.02M-7.54150Positive News
INVA
Innoviva
4.1263 of 5 stars
$20.09
+0.7%
$55.00
+173.8%
+19.9%$1.26B$358.71M-19.89100
DVAX
Dynavax Technologies
4.4224 of 5 stars
$9.92
+0.1%
$24.00
+141.9%
-9.9%$1.19B$277.25M-19.08350Positive News
OPK
OPKO Health
4.4444 of 5 stars
$1.32
flat
$2.75
+108.3%
+8.1%$1.05B$713.10M-18.852,997Positive News
NVAX
Novavax
4.5121 of 5 stars
$6.30
-1.1%
$17.00
+169.8%
-48.1%$1.02B$682.16M2.381,990
GERN
Geron
3.2776 of 5 stars
$1.41
-5.4%
$5.06
+259.0%
-68.2%$898.06M$76.99M-6.7170
RGLS
Regulus Therapeutics
2.0556 of 5 stars
$8.16
flat
$8.50
+4.2%
N/A$564.92MN/A-11.1830Gap Up

Related Companies and Tools


This page (NASDAQ:MNKD) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners